RBC Capital reiterates Exelixis stock rating on competitive position By Investing.com

RBC Capital kept Exelixis at Sector Perform with a $43 price target, implying only 1-2% upside from the current $45.38 share price. The company reported Q4 2025 EPS of $0.97, beating the $0.80 consensus by 21.25%, while revenue of $598.66 million missed the $604.56 million estimate. Analyst views remain mixed as H.C. Wainwright raised its target to $54 and Citizens kept a $50 target, but Merck’s kidney-cancer trial results add competitive pressure.

Analysis

The key signal is not Exelixis’ near-term operating print, but the market’s transition from "single-franchise durability" to "platform durability under competitive pressure." When a dominant competitor slips in RCC, Exelixis gets a temporary sentiment tailwind, but the bigger issue is that investors will start discounting the franchise on patent runway and next-gen pipeline optionality rather than current share stability. That typically compresses upside unless management can prove that zanzalintinib is not just additive but strategically de-risking the post-patent earnings stream.

The asymmetry is that the stock can look optically cheap on earnings multiples while still being fairly valued if the market assigns a steep fade rate to the core asset after patent cliffs. In biotech, a low PEG is often a trap when growth is coming from a mature asset with binary protection risk 2-4 years out; valuation re-rates only if there is credible evidence of a second engine, not just preserved franchise cash flow. The modest analyst upside suggests consensus is already treating the latest competitive setback as a stopgap, not a structural victory.

The cleaner trade is likely in Merck, not Exelixis. If Merck’s RCC data is validated and translated into prescribing momentum, the revenue impact can extend beyond oncology into share-of-wallet gains with payers and treatment-center influence, while pressuring any competitor anchored to monotherapy economics. However, if the market has already capitalized that data as a broad win, the reversal risk is on execution: reimbursement, guideline adoption, and combination-tolerability could slow uptake over the next 1-2 quarters.

Contrarian view: the market may be underestimating how quickly RCC treatment hierarchy can change once survival data, not just PFS, becomes the currency. That means the current read-through is less about one company winning and more about an industry-wide repricing of late-line assets with weaker life-cycle protection. In that setup, the winner is the company with the strongest combination franchise and the cleanest patent wall, not necessarily the one with the best headline trial print today.

Key Decisions for Investors

• Avoid adding to EXEL on the headline; if long, trim into strength over the next 1-2 weeks and wait for a better entry closer to support, since upside looks capped until the pipeline re-accelerates.
• Initiate a tactical long MRK / short EXEL pair for 1-3 months to express the view that competitive oncology share gains are more durable than franchise-defense narratives; target 5-8% relative outperformance with tight stop if EXEL guidance improves.
• Buy EXEL puts or put spreads into any post-news pop over the next 2-6 weeks to fade sentiment overshoot; risk is limited if the market rerates it as a stable cash-flow name, but payoff improves if patent-cliff anxiety returns.
• For longer-duration investors, own MRK on pullbacks only if upcoming adoption metrics confirm that trial results are translating into treatment-pathway share; otherwise, the data may remain a headline win without immediate revenue acceleration.
• Set a catalyst calendar around Exelixis pipeline updates and any NCCN/guideline or payer commentary over the next 1-2 quarters; those are the triggers that can convert a low-multiple value story into a real re-rating.